Our work on C. elegans emphasized the benefits of sharing large amounts of information. We took a global approach to discover the mechanisms that led to the development of the worm.

If we understand the worm, we understand life.

The fact is that proprietary databases don't work for such basic and broadly needed information as the sequence of the human genome.

We're not sharing information with respect to passenger and crew interview data at all. We have never, ever given it up.

Remember the two benefits of failure. First, if you do fail, you learn what doesn't work; and second, the failure gives you the opportunity to try a new approach.

It is very clear that the present system of innovation for medicines is very inefficient and really somewhat corrupt. It benefits shareholders over patients; it produces for the rich markets and not for the poor and does not produce for minority diseases.